News

What’s new with DiaSorin Molecular.

Available here is a selection of our latest news about DiaSorin Molecular.
Filtered by year 2022
Published on 7 Nov 2022

DIASORIN COMMERCIALIZES MOLECULAR REAGENT FOR MONKEYPOX VIRUS

Saluggia, Italy, November 7, 2022 – DiaSorin (FTSE MIB: DIA) announces its release of an Analyte Specific Reagent (ASR) primer pair that detects the B17R/B18R gene of the monkeypox virus, the orthopoxvirus responsible for the ongoing 2022 global public health emergency. The ASR can be used by high-complexity clinical laboratories to develop and validate assays to detect monkeypox virus DNA for diagnostic purposes as well as by non-clinical laboratories to develop and validate tests for research, forensic and other non-clinical purposes.

DiaSorin Molecular
Press Release
Published on 14 Sep 2022

The Simplexa™ COVID-19 Direct Test Receives U.S. FDA 510(K) Clearance

Cypress, Calif. (September 14, 2022) – DiaSorin Molecular announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their Simplexa™ COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of SARS-CoV-2, the virus that causes COVID-19, directly from nasopharyngeal or nasal swab specimens. The Simplexa™ COVID-19 Direct kit is designed for use on the LIAISON® MDX system. This COVID-19 molecular assay can be utilized by hospital or commercial laboratories allowing for timely testing and highly accurate results.

DiaSorin Molecular
Press Release